Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 84.32
NVAX's Cash to Debt is ranked higher than
78% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. NVAX: 84.32 )
NVAX' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 84.32

Equity to Asset 0.90
NVAX's Equity to Asset is ranked higher than
93% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. NVAX: 0.90 )
NVAX' s 10-Year Equity to Asset Range
Min: 0.14   Max: 0.98
Current: 0.9

0.14
0.98
F-Score: 5
Z-Score: 21.63
M-Score: -0.44
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -211.02
NVAX's Operating margin (%) is ranked higher than
64% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. NVAX: -211.02 )
NVAX' s 10-Year Operating margin (%) Range
Min: -11502.46   Max: -38.46
Current: -211.02

-11502.46
-38.46
Net-margin (%) -208.49
NVAX's Net-margin (%) is ranked higher than
64% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. NVAX: -208.49 )
NVAX' s 10-Year Net-margin (%) Range
Min: -12414.15   Max: -40.49
Current: -208.49

-12414.15
-40.49
ROE (%) -31.73
NVAX's ROE (%) is ranked higher than
71% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. NVAX: -31.73 )
NVAX' s 10-Year ROE (%) Range
Min: -155.17   Max: -26.95
Current: -31.73

-155.17
-26.95
ROA (%) -27.63
NVAX's ROA (%) is ranked higher than
69% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. NVAX: -27.63 )
NVAX' s 10-Year ROA (%) Range
Min: -108.43   Max: -13.76
Current: -27.63

-108.43
-13.76
ROC (Joel Greenblatt) (%) -416.11
NVAX's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. NVAX: -416.11 )
NVAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -872.73   Max: -31.47
Current: -416.11

-872.73
-31.47
EBITDA Growth (%) -4.20
NVAX's EBITDA Growth (%) is ranked higher than
78% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. NVAX: -4.20 )
NVAX' s 10-Year EBITDA Growth (%) Range
Min: -58.5   Max: 101.4
Current: -4.2

-58.5
101.4
EPS Growth (%) -3.00
NVAX's EPS Growth (%) is ranked higher than
81% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NVAX: -3.00 )
NVAX' s 10-Year EPS Growth (%) Range
Min: -45.6   Max: 52.3
Current: -3

-45.6
52.3
» NVAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NVAX Guru Trades in Q3 2013

Steven Cohen 13,400 sh (New)
Jean-Marie Eveillard 800,000 sh (New)
George Soros 573,000 sh (New)
» More
Q4 2013

NVAX Guru Trades in Q4 2013

Paul Tudor Jones 26,930 sh (New)
David Swensen 25,398 sh (New)
Jean-Marie Eveillard 800,000 sh (unchged)
George Soros Sold Out
Steven Cohen Sold Out
» More
Q1 2014

NVAX Guru Trades in Q1 2014

Steven Cohen 192,191 sh (New)
Paul Tudor Jones 29,939 sh (+11.17%)
David Swensen Sold Out
Jean-Marie Eveillard 200,000 sh (-75%)
» More
Q2 2014

NVAX Guru Trades in Q2 2014

Paul Tudor Jones 300,000 sh (+902.04%)
Jean-Marie Eveillard 500,000 sh (+150%)
» More
» Details

Insider Trades

Latest Guru Trades with NVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 Add 150%$3.69 - $5.13 $ 4.8510%500000
David Swensen 2014-03-31 Sold Out 0.23%$4.13 - $6.65 $ 4.85-13%0
Jean-Marie Eveillard 2014-03-31 Reduce -75%0.01%$4.13 - $6.65 $ 4.85-13%200000
David Swensen 2013-12-31 New Buy0.23%$2.76 - $5.16 $ 4.8538%25398
George Soros 2013-12-31 Sold Out 0.02%$2.76 - $5.16 $ 4.8538%0
George Soros 2013-09-30 New Buy0.02%$2.25 - $3.39 $ 4.8572%573000
Jean-Marie Eveillard 2013-09-30 New Buy0.01%$2.25 - $3.39 $ 4.8572%800000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.20
NVAX's P/B is ranked higher than
77% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. NVAX: 4.20 )
NVAX' s 10-Year P/B Range
Min: 0.74   Max: 11.13
Current: 4.2

0.74
11.13
P/S 33.20
NVAX's P/S is ranked higher than
69% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.28 vs. NVAX: 33.20 )
NVAX' s 10-Year P/S Range
Min: 5.93   Max: 409
Current: 33.2

5.93
409
EV-to-EBIT -16.82
NVAX's EV-to-EBIT is ranked higher than
76% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NVAX: -16.82 )
NVAX' s 10-Year EV-to-EBIT Range
Min: 24.5   Max: 36.7
Current: -16.82

24.5
36.7
Current Ratio 9.53
NVAX's Current Ratio is ranked higher than
89% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. NVAX: 9.53 )
NVAX' s 10-Year Current Ratio Range
Min: 0.44   Max: 37
Current: 9.53

0.44
37
Quick Ratio 9.53
NVAX's Quick Ratio is ranked higher than
89% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. NVAX: 9.53 )
NVAX' s 10-Year Quick Ratio Range
Min: 0.44   Max: 37
Current: 9.53

0.44
37

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.79
NVAX's Price/Net Cash is ranked higher than
85% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 100.00 vs. NVAX: 9.79 )
NVAX' s 10-Year Price/Net Cash Range
Min: 2.48   Max: 193.8
Current: 9.79

2.48
193.8
Price/Net Current Asset Value 9.42
NVAX's Price/Net Current Asset Value is ranked higher than
84% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 45.54 vs. NVAX: 9.42 )
NVAX' s 10-Year Price/Net Current Asset Value Range
Min: 3.98   Max: 418.8
Current: 9.42

3.98
418.8
Price/Tangible Book 5.67
NVAX's Price/Tangible Book is ranked higher than
79% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 8.50 vs. NVAX: 5.67 )
NVAX' s 10-Year Price/Tangible Book Range
Min: 3.01   Max: 187.5
Current: 5.67

3.01
187.5
Price/Median PS Value 0.81
NVAX's Price/Median PS Value is ranked higher than
89% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 1.80 vs. NVAX: 0.81 )
NVAX' s 10-Year Price/Median PS Value Range
Min: 0.1   Max: 7.63
Current: 0.81

0.1
7.63
Forward Rate of Return (Yacktman) -16.82
NVAX's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. NVAX: -16.82 )
NVAX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -24.5   Max: -17.2
Current: -16.82

-24.5
-17.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NVV.Germany
Novavax, Inc. was incorporated in 1987 under the laws of the State of Delaware. The Company is a clinical-stage Biopharmaceutical Company focused on creating differentiated, value- upon current preventive options for a range of infectious diseases. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ('VLPs') and recombinant nanoparticle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. Its influenza VLPs contain three of the major structural virus proteins that are important for fighting influenza: hemagglutinin (HA) and neuraminidase (NA), both of which stimulate the body to produce antibodies that neutralize the influenza virus and prevent its spread through the cells in the respiratory tract, and matrix 1 (M1), which stimulates cytotoxic T lymphocytes to kill cells that may already be infected. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus ('RSV'). Its product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus (RSV). Further, CPL Biologics Private Limited (the JV), its joint venture Company in India, is actively developing a rabies vaccine candidate that was genetically engineered by Novavax. The JV recently completed initial pre-clinical immunogenicity studies on this new vaccine candidate and is progressing with pre-clinical toxicology studies. The Company's main competitors includes sanofi pasteur, Inc, MedImmune, LLC (a subsidiary of AstraZeneca PLC), GlaxoSmithKline plc, Novartis, Inc., and Merck & Co., Inc. It is also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations.
» More Articles for NVAX

Headlines

Articles On GuruFocus.com
comment on NVAX Mar 16 2013 
comment on NVAX Mar 16 2013 
Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
creiter note on NVAX Jan 03 2010 
Novavax Inc. Reports Operating Results (10-Q) Nov 09 2009 
Novavax Inc. Reports Operating Results (10-Q) Aug 10 2009 
Novavax Reports Second Quarter 2009 Financial Results Aug 07 2009 
Novavax Inc. Reports Operating Results (10-Q) May 11 2009 


More From Other Websites
Novavax (NVAX) Shows Strength: Stock Adds 10.1% in Session Oct 17 2014
Novavax Begins Mid-Stage Study on RSV Vaccine in Elders Oct 15 2014
Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II... Oct 15 2014
Novavax Study Published in Vaccine: RSV F-Protein Nanoparticle Vaccine Induces Antigenic Site II... Oct 15 2014
Novavax Initiates Phase 2 Clinical Trial of RSV Vaccine in Elderly Subjects Oct 14 2014
Insider Trading Alert - BLUE, NVAX And SNCR Traded By Insiders Oct 06 2014
Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax Sep 30 2014
Novavax's Influenza Vaccine Study Shows Adjuvant Efficiency Sep 24 2014
NOVAVAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial... Sep 24 2014
[video] Novavax CEO: Avian Flu Results Very Positive for Vaccine Maker Sep 23 2014
Novavax Announces BARDA Exercise of Contract Option Sep 23 2014
Novavax' H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM) Delivers Positive Phase 1/2... Sep 23 2014
Novavax Initiates Phase 2 Clinical Trial of RSV F-Protein Nanoparticle Vaccine Candidate in Healthy... Sep 16 2014
Novavax to Host 2nd Annual Analyst and Investor Meeting Sep 11 2014
ICAAC Presentation: Immunization of Pregnant Baboons With the RSV F Nanoparticle Vaccine Protects... Sep 08 2014
Novavax Presents Data on RSV F Nanoparticle Vaccine Induced Monoclonal Antibody at ICAAC Sep 06 2014
CORRECTING and REPLACING -- Novavax to Present RSV Vaccine Preclinical Results at ICAAC Sep 03 2014
Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC Sep 03 2014
NOVAVAX INC Financials Aug 15 2014
Novavax (NVAX) Marked As A Dead Cat Bounce Stock Aug 08 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK